固阳化水方治疗脾肾阳虚型糖尿病黄斑水肿的临床研究

张陶陶; 王露露; 肖艳萍; 廖良

固阳化水方治疗脾肾阳虚型糖尿病黄斑水肿的临床研究

1.
北京中医药大学第二临床医学院，北京 100078
2.
北京中医药大学东方医院，北京 100078

计量
- 文章访问数: 619
- HTML全文浏览量: 3
- PDF下载量: 488
- 被引次数: 0
出版历程
- 刊出日期: 2019-11-10

Clinical Study on Guyang Huashui Formula in Treating Diabetic Macular Edema with Spleen and Kidney Yang Deficiency Type

1.
The Second Clinical College of Medicine, Beijing University of Chinese Medicine, Beijing, 100078, China
2.
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China

摘要

摘要: 目的评价固阳化水方治疗脾肾阳虚型糖尿病黄斑水肿（DME）的临床疗效。方法采用前瞻性随机对照试验的研究方法，观察2016年1月至2018年12月在北京中医药大学东方医院眼科门诊就诊的糖尿病黄斑水肿患者66例（66只眼），纳入患者需同时符合糖尿病黄斑水肿国际临床分型中度及以上和中医证型脾肾阳虚型的诊断标准，随机分为试验组和对照组各33例，分别给予固阳化水方中药配方颗粒剂或羟苯磺酸钙胶囊及迈之灵片口服治疗3月，根据患者的最佳矫正视力、黄斑区视网膜厚度和体积、中医证候积分等进行疗效评价。结果 2组各有30例患者完成全部治疗和观察。治疗后2组患者最佳矫正视力较治疗前均有明显改善（P<0.05～0.01），组间差异无显著性意义（P>0.05）；试验组黄斑中心视网膜厚度显著降低（P<0.01），2组黄斑区视网膜体积、黄斑区平均视网膜厚度均明显降低（P<0.01），试验组明显优于对照组（P<0.01）；试验组中医证候积分明显改善（P<0.05～0.01），2组比较，P＜0.05~0.01。结论固阳化水方可明显改善糖尿病黄斑水肿患者视力并降低黄斑区视网膜厚度，显著缓解患者中医症状。
- 固阳化水方 /
- 糖尿病黄斑水肿 /
- 脾肾阳虚 /
- 光学相干断层成像 /
- 黄斑中心厚度
Abstract: OBJECTIVE To evaluate the clinical efficacy of Guyang Huashui formula in treating diabetic macular edema (DME) with spleen and kidney yang deficiency type. METHODS A prospective randomized controlled trial was conducted to observe 66 patients (66 eyes) with DME outpatients in the department of ophthalmology in Dongfang Hospital from January in 2016 to December in 2018. Patients admitted to the study should meet the diagnostic criteria for moderate and worse international clinical classification of DME and traditional Chinese medicine (TCM) syndrome type of spleen and kidney yang deficiency. Randomly divided into the experimental group and the control group， 33 cases each， who were given Guyang Huashui formula granules or calcium hydroxybenzenesulfonate capsules and Maizhiling tablets for oral treatment for 3 months. The efficacy was evaluated according to the patient's best corrected visual acuity， macular retinal thickness and volume， and TCM syndrome scores. RESULTS 30 patients in each group completed all treatment and observation. After treatment， the best corrected visual acuity in both groups was significantly improved compared with that before treatment (P<0.05， P<0.01 ) and difference between groups has no significant meaning (P>0.05). The thickness of the retinal film in the macular center of the test group was significantly reduced (P<0.01 ). The thickness of the retinal membrane and the average thickness of the retinal membrane in the macular area of the two groups were significantly reduced (P<0.01)， and the test group was significantly better than the control group (P<0.01). In the trial group， the medical syndrome was clearly improved (P<0.05， P<0.01). The two groups were compared and the difference was significant (P<0.05， P<0.01). CONCLUSION Guyang Huashui formula can significantly improve DME patient's vision and reduced retinal thickness in the macular area so as to relieve their TCM syndrome.
- Guyang Huashui formula /
- diabetic macular edema /
- spleen and kidney yang deficiency /
- optical coherence tomography /
- macular center thickness

HTML全文

参考文献(22)

[1]	WONG TY， SUN J， KAWASAKI R， et al. Guidelines on diabetic eye care: The international council of ophthalmology recommendations for screening， follow-up， referral， and treatment based on resource settings[J]. Ophthalmology， 2018， 125(10):1608-1622.
[2]	SOLOMON SD， CHEW E， DUH EJ，et al. Diabetic retinopathy: A position statement by the American diabetes association [J]. Diabetes Care， 2017， 40(3):412-418.
[3]	YANG W， LU J， WENG J， et al. Prevalence of diabetes among men and women in China [J]. N Eng J Med， 2010，362(12):1090-1101.
[4]	洪天配，杨进. 中国糖尿病防治的转化医学研究:机遇与挑战[J]. 中华糖尿病杂志，2017， 9（12）：729-731.
[5]	中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014版)[J].中华眼科杂志，2014，50(11):851-863.
[6]	惠延年，王琳. 糖尿病视网膜病变和糖尿病黄斑水肿的国际临床分类法[J].中华医学信息导报，2004，19（10）：16.
[7]	彭清华. 中医眼科学[M].北京: 中国医药科技出版社，2016：176.
[8]	国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社，2002:74-77.
[9]	BROWNING DJ， EDITOR.Diabetic Retinopathy， Evidence-Based Management[M]. New York: Springer Inc， 2010: 142-147.
[10]	VINORES SA， MCGEHEE R， LEE A， et al. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats [J]. J Histochem Cytochem， 1990，38:1341-1352.
[11]	GANDORFER A. Role of vitreous in diabetic macular edema [J]. Retina， 2012， 32(S2):S211-215.
[12]	MIYAMOTO K，KHOSROF S， BURSELL SE， et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)[J]. Am J Pathol， 2000，156:1733-1739.
[13]	LUND-ANDERSEN H. Mechanisms for monitoring changes in retinal status following therapeutic intervention in diabetic retinopathy [J]. Surv Ophthalmol， 2002，47(S2):270-277.
[14]	TANG J， KERN TS. Inflammation in diabetic retinopathy [J]. Prog Retin Eye Res， 2011，30:343-358.
[15]	NAGAOKA T，KITAYA N， SUGAWARA R， et al. Alteration of choroidal circulation in the foveal region in patients with type 2 diabetes [J]. Br J Ophthalmol， 2004， 88:1060-1063.
[16]	BROWNING DJ， GLASSMAN AR， AIELLO LP，et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema [J]. Ophthalmology， 2008，115:1366-1371.
[17]	ELIWA TF， HUSSEIN MA， ZAKI MA，et al. Outer retinal layer thickness as good visual predictor in patients with diabetic macular edema [J]. Retina， 2018，38:805-811.
[18]	MATURI RK， POLLACK A， UY HS， et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study [J]. Retina， 2016，36:1143-1152.
[19]	NGUYEN QD， BROWN DM， MARCUS DM， et al. Ranibizumab for diabetic macular edema: Results from 2 phase Ⅲ randomized trials: RISE and RIDE [J]. Ophthalmology， 2012，119:789-801.
[20]	BRESSLER NM， BEAULIEU WT， GLASSMAN AR， et al. Persistent macular thickening followingintravitreous aflibercept， bevacizumab， or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial [J]. JAMA Ophthalmol， 2018，136:257-269.
[21]	SOHEILIAN M， GARFAMI KH， RAMEZANI A，et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema [J]. Retina， 2012，32:314-321.
[22]	FIGUEROA MS， CONTRERAS I，NOVAL S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema [J]. Retina， 2008，28:420-426.